CN1665528B - 佐剂病毒颗粒 - Google Patents

佐剂病毒颗粒 Download PDF

Info

Publication number
CN1665528B
CN1665528B CN03815935XA CN03815935A CN1665528B CN 1665528 B CN1665528 B CN 1665528B CN 03815935X A CN03815935X A CN 03815935XA CN 03815935 A CN03815935 A CN 03815935A CN 1665528 B CN1665528 B CN 1665528B
Authority
CN
China
Prior art keywords
virus
immunogen
particle
application
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN03815935XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1665528A (zh
Inventor
德尼·勒克莱尔
纳塔莉·马杰奥
菲利普·泰西耶
康斯坦丁诺·三氏·罗伯托·洛佩斯－马西亚斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Folia Biotech Inc
Original Assignee
Folia Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Folia Biotech Inc filed Critical Folia Biotech Inc
Publication of CN1665528A publication Critical patent/CN1665528A/zh
Application granted granted Critical
Publication of CN1665528B publication Critical patent/CN1665528B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/26011—Flexiviridae
    • C12N2770/26023—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN03815935XA 2002-07-05 2003-06-30 佐剂病毒颗粒 Expired - Fee Related CN1665528B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39365902P 2002-07-05 2002-07-05
US60/393,659 2002-07-05
PCT/CA2003/000985 WO2004004761A2 (en) 2002-07-05 2003-06-30 Adjuvant viral particle

Publications (2)

Publication Number Publication Date
CN1665528A CN1665528A (zh) 2005-09-07
CN1665528B true CN1665528B (zh) 2013-05-15

Family

ID=30115621

Family Applications (1)

Application Number Title Priority Date Filing Date
CN03815935XA Expired - Fee Related CN1665528B (zh) 2002-07-05 2003-06-30 佐剂病毒颗粒

Country Status (14)

Country Link
US (2) US7641896B2 (enExample)
EP (2) EP2272525A3 (enExample)
JP (1) JP4953570B2 (enExample)
KR (1) KR20050044886A (enExample)
CN (1) CN1665528B (enExample)
AU (1) AU2003281246A1 (enExample)
BR (1) BR0312474A (enExample)
CA (1) CA2434000C (enExample)
DK (1) DK1523329T3 (enExample)
ES (1) ES2431963T3 (enExample)
MX (1) MXPA05000287A (enExample)
NO (1) NO20050396L (enExample)
PT (1) PT1523329E (enExample)
WO (1) WO2004004761A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2434000C (en) * 2002-07-05 2012-07-17 Denis Leclerc Adjuvant viral particle
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
JP2008513035A (ja) * 2004-09-21 2008-05-01 サイトス バイオテクノロジー アーゲー Ａｐ２０５のコートタンパク質と抗原性ポリペプチドとの融合タンパク質を含んでなるウイルス粒子
CN101119749A (zh) 2004-10-25 2008-02-06 赛托斯生物技术公司 肠抑胃肽(gip)抗原阵列及其用途
KR100688522B1 (ko) * 2005-01-18 2007-03-02 삼성전자주식회사 영상데이터 압축기 및 압축방법
WO2007053188A2 (en) 2005-06-01 2007-05-10 Dow Global Technologies, Inc. Production of multivalent virus like particles
AT503690A1 (de) 2006-06-09 2007-12-15 Biomay Ag Hypoallergene moleküle
EP2078086A4 (en) * 2006-11-15 2010-06-30 Folia Biotech Inc PAPAYAMOSAIC VIRUS-BASED IMMUNOGENE AFFINITY-CONJUGATED ANTIGENSYSTEMS AND THEIR USES
WO2012048430A1 (en) * 2010-10-14 2012-04-19 Folia Biotech Inc. Affinity-conjugated nucleoprotein-papaya mosaic virus-like particles and uses thereof
CA2669485C (en) * 2006-11-15 2017-01-03 Folia Biotech Inc. Papaya mosaic virus-based vaccines for influenza
JP2010516713A (ja) * 2007-01-26 2010-05-20 フォーリア バイオテック インコーポレーテッド 腸チフス菌および他の腸内細菌病原体に対するパパイアモザイクウィルスベースのワクチン
US20090093019A1 (en) * 2007-04-27 2009-04-09 Phelps Jamie P Production and in vivo assembly of soluble recombinant icosahedral virus-like particles
JP2010538619A (ja) * 2007-09-11 2010-12-16 ユニベルシテ ラヴァル Ｍａｌｖａモザイクウイルスおよびウイルス様粒子およびこれらの使用
US20110189231A1 (en) * 2008-06-17 2011-08-04 Denis Leclerc Compositions Comprising Salmonella Porins and Uses Thereof as Adjuvants and Vaccines
WO2010012069A1 (en) * 2008-07-30 2010-02-04 Folio Biotech Inc. Multivalent vaccines based on papaya mosaic virus and uses thereof
WO2012078069A1 (en) 2010-12-09 2012-06-14 Iosif Grigorievich Atabekov Spherical nano- and microparticles derived from plant viruses for the display of foreign proteins or epitopes
AU2012255595A1 (en) 2011-05-13 2013-12-12 Folia Biotech Inc. Virus-like particles and process for preparing same
TR201905619T4 (tr) 2011-06-09 2019-05-21 Biomay Ag Alerji aşısı olarak peptit taşıyıcı füzyon proteinleri.
HK1203983A1 (en) * 2012-04-02 2015-11-06 Folia Biotech Inc. Recombinant papaya mosaic virus coat proteins and uses thereof in influenza vaccines
JP2016531927A (ja) * 2013-09-19 2016-10-13 フォリア バイオテック インコーポレイテッド 癌治療でのパパイヤモザイクウイルス及びウイルス様粒子
WO2016176558A1 (en) * 2015-04-30 2016-11-03 The Regents Of The University Of California Adjuvant particles comprising adenosine receptor antagonists
CN115956125A (zh) * 2020-03-31 2023-04-11 医学噬菌体生物制药公司 用于产生病毒样颗粒的载体及其用途
EP4277654A1 (en) 2021-01-18 2023-11-22 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
CN118684781A (zh) * 2023-03-21 2024-09-24 深圳赫兹生命科学技术有限公司 GnRH-VLP重组去势疫苗及其制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79880A0 (en) 1985-08-29 1986-11-30 Inst Medical W & E Hall Recombinant virus
US5977438A (en) 1988-02-26 1999-11-02 Biosource Technologies, Inc. Production of peptides in plants as viral coat protein fusions
DE4006630A1 (de) 1990-03-03 1991-09-12 Behringwerke Ag Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
CA2089497A1 (en) 1990-08-15 1992-02-16 Lendon Payne Self-assembling replication defective hybrid virus particles
US5443969A (en) * 1992-10-29 1995-08-22 Rutgers University RNA packaging system
GB9414118D0 (en) 1994-07-13 1994-08-31 Axis Genetics Ltd Modified plant viruses as vectors of heterologous peptides
CA2202761A1 (en) 1994-10-18 1996-04-25 Sean Nicholas Chapman Method of producing a chimeric protein
GB9607899D0 (en) 1996-04-17 1996-06-19 Scottish Crop Research Inst Virus-like particle
US6042832A (en) 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
EP0980257A1 (en) * 1997-05-01 2000-02-23 Chiron Corporation Use of virus-like particles as adjuvants
US6228368B1 (en) 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
DE19752855C2 (de) 1997-11-28 2003-04-03 Bundesrepublik Deutschland Let Retrovirale Pseudotyp-Vektoren mit modifizierten Oberflächen-Hüllproteinen und Verpackungszelle zu ihrer Herstellung für den selektiven Gentransfer
GB9806666D0 (en) 1998-03-27 1998-05-27 Stanley Margaret Antigen preparation and use
JP2002522029A (ja) 1998-07-27 2002-07-23 ジェネンテック・インコーポレーテッド コートタンパク質の改変によるファージ提示における改良した形質転換効率
FR2786773B1 (fr) 1998-12-03 2002-03-08 Univ Paris Curie Proteines d'enveloppe, methodes et utilisations
EP2351768B1 (en) 1998-12-04 2014-06-18 Biogen Idec MA Inc. HBV core antigen particles with multiple immunogenic components attached via peptide ligands
DE19904800C1 (de) 1999-02-05 2001-02-08 Eberhard Hildt Partikel zur Gentherapie
GB9921337D0 (en) * 1999-09-09 1999-11-10 Axis Genetics Plc Modified plant viruses
GB9924352D0 (en) 1999-10-14 1999-12-15 Hellendoorn Koen Methods,compositions and applications relating to the generation of novel plant viral particles
GB9924351D0 (en) * 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
US6730306B1 (en) 2000-03-08 2004-05-04 Large Scale Biology Corporation Parvovirus vaccine as viral coat protein fusions
AUPQ661600A0 (en) 2000-03-31 2000-05-04 Macfarlane Burnet Centre For Medical Research Limited, The A nucleic acid construct and methods related thereto
IT1317046B1 (it) * 2000-06-16 2003-05-26 Ist Superiore Sanita Proteina di fusione, particelle virali chimeriche che la espongono sulcapside, piante infettate con tali particelle, loro usi e composizioni
CA2414396A1 (en) 2000-06-26 2002-01-03 The United States Of America, As Represented By The Secretary Of Agricul Ture Production of vaccines using transgenic plants
WO2002004007A2 (en) 2000-07-06 2002-01-17 Georgetown University Stable (fixed) forms of viral capsid proteins, fusion proteins and uses thereof
GB0028319D0 (en) * 2000-11-20 2001-01-03 Univ Southampton Materials and methods relating to fusion proteins for inducing an immune response
ITRM20010332A1 (it) * 2001-06-11 2002-12-11 Ist Superiore Sanita Vaccini a subunita' e procedimenti per la loro produzione.
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
CA2434000C (en) * 2002-07-05 2012-07-17 Denis Leclerc Adjuvant viral particle

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
马光恕等.瓜类作物病毒病的研究进展.黑龙江农业科学 1.2001,1第45页左栏.
马光恕等.瓜类作物病毒病的研究进展.黑龙江农业科学 1.2001,1第45页左栏. *

Also Published As

Publication number Publication date
US20090280145A1 (en) 2009-11-12
US8282940B2 (en) 2012-10-09
BR0312474A (pt) 2005-04-26
HK1075214A1 (en) 2005-12-09
NO20050396L (no) 2005-01-25
WO2004004761A3 (en) 2004-05-06
EP2272525A3 (en) 2011-11-16
DK1523329T3 (da) 2013-10-14
KR20050044886A (ko) 2005-05-13
CA2434000C (en) 2012-07-17
AU2003281246A1 (en) 2004-01-23
EP2272525A2 (en) 2011-01-12
WO2004004761A2 (en) 2004-01-15
EP1523329B1 (en) 2013-07-24
US20050048082A1 (en) 2005-03-03
ES2431963T3 (es) 2013-11-28
JP2006504644A (ja) 2006-02-09
CA2434000A1 (en) 2004-01-05
MXPA05000287A (es) 2005-09-08
CN1665528A (zh) 2005-09-07
US7641896B2 (en) 2010-01-05
JP4953570B2 (ja) 2012-06-13
PT1523329E (pt) 2013-10-08
EP1523329A2 (en) 2005-04-20

Similar Documents

Publication Publication Date Title
CN1665528B (zh) 佐剂病毒颗粒
Francis Recent advances in vaccine technologies
Steward et al. Synthetic peptides: a next generation of vaccines?
Azegami et al. Challenges in mucosal vaccines for the control of infectious diseases
ES2139879T5 (es) Adyuvante de la mucosa no toxico.
Brennan et al. Pseudomonas aeruginosa outer-membrane protein F epitopes are highly immunogenic in mice when expressed on a plant virus
TWI620574B (zh) 口蹄疫合成胜肽緊急疫苗
Azegami et al. Novel transgenic rice-based vaccines
Artnzen Edible vaccines
Smith et al. Display of peptides on the surface of tobacco mosaic virus particles
Cañas‐Arranz et al. A bivalent B‐cell epitope dendrimer peptide can confer long‐lasting immunity in swine against foot‐and‐mouth disease
McCLUSKIE et al. Immunization against hepatitis B virus by mucosal administration of antigen–antibody complexes
CN102168088A (zh) T细胞免疫原基因ti及其在口蹄疫蛋白亚单位疫苗和灭活疫苗中的应用
US9119803B2 (en) Carious tooth vaccine and preparation method
CN101293098A (zh) 一种重组牛o型口蹄疫病毒融合蛋白疫苗
Leong Molecular and biotechnological approaches to fish vaccines
Agterberg et al. Protection of guinea-pigs against foot-and-mouth disease virus by immunization with a PhoE-FMDV hybrid protein
CN113248575A (zh) 一种针对SARS-CoV-2的重组蛋白疫苗及其制备方法
Murdin et al. Synthetic peptide vaccines against foot-and-mouth disease. I. Duration of the immune response and priming in guinea-pigs, rabbits and mice
Roitt Basic concepts and new aspects of vaccine development
HK1151730A (en) Adjuvant viral particle
Yu et al. A DNA vaccine encoding the FMDV capsid precursor polypeptide P1 and the enhancing effect of bovine herpesvirus 1 VP22 protein as molecular adjuvant
KR20240054479A (ko) 바이러스 표면 엔지니어링 기반의 면역 증강된 돼지 유행성 설사병 바이러스 백신
CN109422813A (zh) HBs-α317ScFv重组蛋白、其编码序列、表达载体及应用
Moore et al. Idiyotype Vaccines

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: FEULLIAS BIOTECHNOLOGY COMPANY

Free format text: FORMER OWNER: LECLERC DENIS

Effective date: 20100712

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: QUEBEC, CANADA TO: QUEBEC CITY, QUEBEC, CANADA

TA01 Transfer of patent application right

Effective date of registration: 20100712

Address after: Quebec, Quebec, Canada

Applicant after: FOLIA BIOTECH INC.

Address before: Quebec

Applicant before: Leclerc Denis

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130515

Termination date: 20180630